A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer

Japanese Journal of Clinical Oncology

Volumn 31, Issue 12, 2001, Pages 596-600

  Hotta, Katsuyuki ^a   Sekine, Ikuo ^a   Tamura, Tomohide ^a   Sawada, Masahiro ^a   Watanabe, Hirokazu ^a   Kusaba, Hitoshi ^a   Akiyama, Yoshiko ^a   Inoue, Akira ^a   Shimoyama, Tatsu ^a   Nokihara, Hiroshi ^a   Ueda, Yutaka ^a   Yamamoto, Noboru ^a   Kunitoh, Hideo ^a   Ohe, Yuichiro ^a   Kodama, Tetsuro ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cisplatin; Non small cell lung cancer; Vinorelbine

Indexed keywords

CISPLATIN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; INFECTION; INJECTION SITE; JAPAN; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SCORING SYSTEM; SELF REPORT; SKIN MANIFESTATION; TOXICITY TESTING;

EID: 0035706846     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hye129     Document Type: Article

References (26)

1. Rare pulmonary tumors - A review of 32 cases
2. Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small cell lung cancer
3. Novel combination chemotherapy in the treatment of non-small cell lung cancer
4. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer
5. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
6. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A South West Oncology Group Study
7. Phase II trial of i.v. vinorelbine and cisplatin in inoperable locally advanced or disseminated non-small-cell lung cancer: The South African Experience
8. Vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: Results of a multicenter Czech study
9. Phase I clinical study of KW-2307 combined with cisplatin in non-small cell lung cancer patients
10. Randomized trial comparing cisplatin, gemcitabine and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group
11. Superiority of 3-week vs. 4-week schedule of cisplatin (CDDP) and gemcitabine (GEM): Results of a randomized phase II study
12. The Japanese edition of the National Cancer Institute - Common Toxicity Criteria
13. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes
14. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: Ethnic distribution and implications for prostate cancer risk
15. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
16. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients
17. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4
18. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins
19. Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine)
20. A randomized trial for effective prevention of navelbine (NVB) and related phlebitis
21. Phase I clinical study of new vinca alkaloid derivative, KW-2307 (Vinorelbine)
22. Multicenter phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients
23. Multicenter randomized clinical trial on high-dose epirubicin plus cisplatinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer
24. Vinorelbine plus cisplatin for the treatment of stage IIIB and IV non small cell lung carcinoma
25. Cisplatin-vinorelbine combination chemotherapy in locally advanced non-small cell lung cancer